Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00939133
Recruitment Status : Completed
First Posted : July 14, 2009
Last Update Posted : February 10, 2015
Johnson & Johnson
Information provided by (Responsible Party):
Ronald Vender MD FRCPC, Dermatrials Research

July 11, 2009
July 14, 2009
February 10, 2015
July 2009
December 2010   (Final data collection date for primary outcome measure)
Primary objectives-to assess the efficacy of Retin A micro 0.04% on the recurrence rate of acne post isotretinoin use compared to vehicle. [ Time Frame: Six Months ]
Same as current
Complete list of historical versions of study NCT00939133 on Archive Site
  • The percent change in lesion counts from baseline to week 16 and 24. [ Time Frame: Six Months ]
  • Proportion of subjects who have a Subject's Global [ Time Frame: Assessment score of 0 or 1 at week 16 and 24 ]
  • Proportion of subjects who have an ISGA score of 0 or 1 at week 16 and 24. [ Time Frame: At week 16 and 24 ]
Same as current
Not Provided
Not Provided
Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin
Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use

The use of topical retinoids is a mainstay and basis of early acne treatment to prevent the progression to inflammatory lesions. Post oral isotretinoin, it is not uncommon for non-inflammatory papules and comedones to recur. However, there has been no formal study to look at the prevention of recurrence of these acne lesions post isotretinoin in a long term basis. This may enhance the therapeutic options for post isotretinoin patients in order to prevent recurrence of their disease.

Hypothesis Tretinoin microsphere 0.04% will prevent recurrence of acne lesions.

Subjects will be randomized 1:1 to study product or vehicle. Subjects will be randomly assigned to each group by an unblinded dispenser.

The study duration will be 24 weeks with visits at baseline (week 0), week 4, week 8, week 16 and week 24. All study products will be administered once daily for 24 weeks. Subjects will apply a sufficient amount of study product to cover the entire face.

Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Drug: tretinoin microsphere 0.04% gel
    Applied daily to entire face for six months
    Other Name: Retin A micro 0.04%
  • Drug: vehicle gel
  • Active Comparator: Tretinoin microsphere 0.04% gel
    Intervention: Drug: tretinoin microsphere 0.04% gel
  • Placebo Comparator: Vehicle gel
    Intervention: Drug: vehicle gel
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be eligible for study admission:

  • Males aged between 18 and 45 years old who have successfully completed a treatment of acne with oral isotretinoin (Min 4 months/Maximum 6 months with an average of 5 months and a total of 120-150mg/kg/course).
  • Who can attend scheduled study follow-up visits at the outpatient dermatology clinic.
  • Agree to informed consent for participation in a study.
  • Agree to comply with the treatment and follow up procedures.

Exclusion Criteria:

  • Patients who receive isotretinoin for condition other than acne vulgaris.
  • Patients who have been off isotretinoin for less than 30 days or more than 90 days at the time of enrollment of the study.
  • Patients who have used prescription topical acne treatment (tretinoin, benzoyl peroxide, topical antibiotics or any combination products) between the end of therapy of isotretinoin within 2 weeks of study enrollment or oral antibiotics of any type between the end of therapy of isotretinoin within 4 weeks of study enrollment and throughout the study.
  • Patients who have been previously diagnosed with an endocrinological disorder likely to cause acne such as genital/adrenal hyperplasia, adrenal tumors or any other hypo androgenetic state.
  • Patients who are using any of the systemic medications likely to cause or abate acne such as oral Dilantin or any other epileptic, Finasteride, Spironolactone or Flutamine, testosterone or dietary body-building protein powders.
  • Have any nodulo-cystic lesions at baseline.
  • Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable.
  • Are currently using any medication that in the opinion of the investigator may affect the action or evaluation of the study product or place the subject at undue risk.
  • Used abradants, facials, peels containing glycolic or other acids; masks, washes, or soaps containing BPO, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers; moisturizers that contain retinol, salicylic acid, or α- or β-hydroxy acids within the past 2 weeks.
  • Plan to use medications that are reported to exacerbate acne (e.g., mega-doses of certain vitamins, such as vitamin D [> 2000 IU per day] and vitamin B12 [> 1 mg/day], haloperidol, halogens [e.g., iodide and bromide], lithium, hydantoin, and phenobarbital), because these may impact efficacy assessments. Subjects who plan to use multivitamins, iron supplements and folate are acceptable.
  • Had a facial procedure (such as chemical or laser peel, microdermabrasion, blue light treatment, etc) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or if it is planned to be performed during the conduct of the study.
  • Have a known hypersensitivity or have had previous allergic reaction to any of the active components or excipients of the study product.
  • Used any investigational therapy within the past 4 weeks, or currently participating in another clinical study.
  • Are currently abusing drugs or alcohol (drug screening not required).
  • Have a significant medical history of being immunocompromised.
  • Have other conditions that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.
  • Had any major illness within 30 days before the screening examination.
  • Currently are employees of R Vender, an investigator, or contract research organization (CRO) involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.
Sexes Eligible for Study: Male
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Ronald Vender MD FRCPC, Dermatrials Research
Dermatrials Research
Johnson & Johnson
Principal Investigator: Ronald Vender, MD FRCPC Dermatrials Research
Dermatrials Research
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP